Key result
LMWH is linked to a ~98% live birth rate in pregnant women with oligohydramnios.
Why the study?
Oligohydramnios is associated with poor fetal outcomes and maternal risks, and the impact of low molecular weight heparin on pregnancy outcomes in this condition requires evaluation.
Does low molecular weight heparin improve pregnancy outcomes in pregnant women with oligohydramnios?
Cohort (n=122)
No
Does low molecular weight heparin improve pregnancy outcomes in pregnant women with oligohydramnios?
LMWH 40 mg daily in pregnant women with oligohydramnios was associated with a 98.4% live birth rate and low adverse perinatal outcomes.
Answers are grounded in this paper and cite their sources.
LMWH merits evaluation in oligohydramnios; leaves open benefit versus controls and requires RCTs before practice change.
Oligohydramnios refers to an antenatal condition in which the amniotic fluid volume is abnormally low and has poor fetal consequences. This research strives to elaborate on the convoluted connections between oligohydramnios and the associated maternal and fetal risks. Objectives: To find out the frequency of pregnancy outcomes in pregnant women with oligohydramnios using low molecular weight heparin (LMWH). Methods: The prospective cohort study was conducted at the Obstetrics Department of Nishtar Hospital, Pakistan from November 2024 to January 2025. One hundred and twenty-two women fulfilling the inclusion criteria were included. Patients were given 40 mg LMWH subcutaneously once a day. The patients were followed till delivery to determine outcomes including live birth, preterm delivery, weight at birth, admission to the Neonatal Intensive Care Unit (NICU) and pre-eclampsia. SPSS version 26.0 was employed to analyze the data. Results: Out of 122 participants, 120 (98.4%) resulted in live births while 2 (1.6%) were intra-uterine deaths. Among all births, 21 (17.2%) were delivered preterm while 101 (82.8%) were delivered at term. 108 (88.5) weighed >2.5 kg. Among 120 live births, 23 (19.2%) were admitted to the NICU for observation or treatment. Conclusions: It was concluded that the study results support the use of LMWH in oligohydramnios as a proportion of adverse perinatal outcomes was low in our study. LMWH was found to be efficacious, authentic and safe in oligohydramnios to achieve desired clinical outcomes and decrease the burden of associated morbidities and mortalities in the targeted population.
No takes yet. Share an insight, caveat, or question.
Tabassum et al. (2025) conducted a cohort in Oligohydramnios (n=122). Low molecular weight heparin (LMWH) was evaluated on Live birth rate. In pregnant women with oligohydramnios, treatment with low molecular weight heparin resulted in a 98.4% live birth rate and an 82.8% term delivery rate.
Synapse has enriched 10 related papers. Consider them for comparative context: